 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | MAM01 / Atreca, Bill & Melinda Gates Foundation
Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population (clinicaltrials.gov) - Oct 29, 2024
P1, N=139, Not yet recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
N=264 --> 139 | Trial completion date: May 2026 --> Jan 2026 | Initiation date: Sep 2024 --> Jan 2025 | Trial primary completion date: May 2026 --> Jan 2026
- | MAM01 / Atreca, Bill & Melinda Gates Foundation
Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults (clinicaltrials.gov) - Oct 29, 2024
P1, N=61, Recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
N=264 --> 139 | Trial completion date: May 2026 --> Jan 2026 | Initiation date: Sep 2024 --> Jan 2025 | Trial primary completion date: May 2026 --> Jan 2026 Trial primary completion date: Mar 2025 --> Dec 2024
- MAM01 / Atreca, Bill & Melinda Gates Foundation
Pharmacokinetics and efficacy of MAM01, anti-circumsporozoite protein (CSP) monoclonal antibody, in mice (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 26, 2024 - Abstract #ASTMH2024ASTMH_4084;
In this study MAM01 demonstrated dose-dependent protection (up to 100%) in both models. Clinical studies with MAM01 are ongoing.
- L9LS / National Institute of Allergy and Infectious Diseases, MAM01 / Atreca, Bill & Melinda Gates Foundation
190 - Clinical Development of Monoclonal Antibodies that Target Malaria Sporozoites (Convention Center - Room 393/394 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_827;
Each presenter will provide an overview on prior experience exploring some of these concepts in prior and current projects, but also will discuss important concepts to explore in future mAb clinical trials. Ample time will be provided at the end of the symposium to promote Q&A and discussion from the audience.
- MAM01 / Atreca, Bill & Melinda Gates Foundation
MAM01: Safety, PK and Preliminary Efficacy of a new 1st gen CSP Monoclonal Antibody (Convention Center - Room 393/394 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_270;
- | MAM01 / Atreca, Bill & Melinda Gates Foundation
New P1 trial: Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population (clinicaltrials.gov) - May 9, 2024
P1, N=264, Not yet recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
- | MAM01 / Atreca, Bill & Melinda Gates Foundation
Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults (clinicaltrials.gov) - Jan 1, 2024
P1, N=61, Recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
- | MAM01 / Atreca, Bill & Melinda Gates Foundation
Enrollment open: Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults (clinicaltrials.gov) - Aug 25, 2023
P1, N=61, Recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
Ample time will be provided at the end of the symposium to promote Q&A and discussion from the audience. Not yet recruiting --> Recruiting
- | MAM01 / Atreca, Bill & Melinda Gates Foundation
New P1 trial: Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults (clinicaltrials.gov) - Jun 6, 2023
P1, N=61, Not yet recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute